StocksMedium•29 September 2026•
1 min read
Novo Nordisk Licenses Hengrui Obesity Drug in $2.6 Billion Deal
Key Facts
1Jiangsu Hengrui Pharmaceuticals signed a licensing deal with Novo Nordisk for global rights to its weight-management drug HRS-1596.
2The total potential value of the deal is up to $2.6 billion, including upfront and milestone payments.
Jiangsu Hengrui Pharmaceuticals signed a licensing deal with Novo Nordisk for the global rights to its weight-management drug HRS-1596. Reuters reported that the total potential value of the deal is up to $2.6 billion, which includes upfront payments and various development milestones.
Novo Nordisk is expanding its pipeline in the highly competitive obesity drug market by acquiring promising candidates from international partners. The company's stock, NONOF, closed at $38.38 on September 28, 2026, after trading between a session low of $37.44 and a high of $38.85.